Speaker: Dr Rugter Zietsma, CEO, Manus Neurodynamica

Rutger is founding CEO of Edinburgh-based Manus Neurodynamica Ltd – the company that created the NeuroMotor PenTM (NMP). The NMP is a medical device which objectively and accurately assesses movement abnormalities to aid in the diagnosis and monitoring of neuromotor impairments. While working with a small consulting firm, Rutger developed ideas to utilise neuroscience from his earlier PhD research to create novel, easily implementable clinical tools. Manus was founded as a channel to realise those ideas. Rutger also instigated the EU project DiPAR in 2010 after raising the funding (EU FP7 Research for SME program) to undertake the R&D and clinical validation for the NMP with 8 other EU partnering organisations. Rutger had the end responsibility for the financial and consortium management and DiPAR delivered all of its objectives. Prior to his PhD, Rutger gained experience in biomedical engineering (J&J Cordis Europe, Philips DAP and Medical systems) and project management for the Dutch healthcare sector (Cap Gemini). He also completed post-graduate courses in Bioengineering and Business administration.

Manus Neurodynamica:

A movement disorder diagnosis and monitoring company with novel sensor and AI technology.

Recently granted "Breakthrough device" status by the FDA for differentiating between Parkinsonian (PD) and non-Parkinsonian tremors

In the EU and US combined there are more than 25 million patients with tremor (including Parkinson’s); representing a potential multi-billion recurring revenue stream for NMP in tremor differentiation.

Location: UK Presentation Theatre: Hall 16, J48